Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wireless Iontophoresis of Neostigmine and Glycopyrrolate
NCT06351852Phase 1Completed
- Sponsor
- James J. Peters Veterans Affairs Medical Center
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neostigmine and glycopyrronium in neurogenic bowel (NBD), constipation and fecal incontinence (FI), sponsored by James J. Peters Veterans Affairs Medical Center. Primary endpoints: Presence or absence of bowel evacuation at 2 hours, Time to bowel evacuation at 2 hours and 3 more. Started Mar 2022; status: completed.
02
Drugs
neostigmineglycopyrronium
03
Conditions
neurogenic bowel (NBD)constipationfecal incontinence (FI)
Beyond the preview
Go deeper on NCT06351852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351852.